Introduction {#Sec1}
============

HIV infection can cause a wide spectrum of central nervous system (CNS) complications ranging from mild neurocognitive impairments to incapacitating dementias that have been recently grouped under the term HIV-associated neurocognitive disorders or HAND (Antinori et al. [@CR2]). Historically, HIV-associated dementia (HIV-D or HAD) was the most prominent manifestation of HIV-mediated brain disease (Epstein et al. [@CR23]; Navia and Price [@CR65]). The introduction of highly efficacious antiretroviral therapies (ART) has markedly reduced the prevalence of HAD but it has had a limited effect on the two other major manifestations of HAND, the HIV-associated asymptomatic neurocognitive impairment (ANI) and the HIV-associated mild neurocognitive disorder (MND) (Sacktor et al. [@CR81]; Ellis et al. [@CR21]; Robertson et al. [@CR79]). By some accounts, up to 50 % of HIV-infected individuals will develop some form of neurocognitive impairment despite access to ART (Ellis et al. [@CR21]; Heaton et al. [@CR35]; Simioni et al. [@CR87]; Harezlak et al. [@CR33]). As HIV infection has become a chronic and manageable condition under ART (Richman [@CR78]), the populations at risk of HAND may begin overlapping with populations prone to other chronic diseases of the central nervous system such as AD (Alisky [@CR1]; Pulliam [@CR75]) and MS (Berger et al. [@CR4]; Lackner et al. [@CR51]). If brain diseases of diverse etiologies utilize common biological pathways in the nervous system, coexistence of such pathologies in a patient may lead to increased morbidity. On the other hand, identification of such common pathogenic pathways may suggest common therapeutic approaches to diverse diseases.

A number of commonalities between HAND and other neurodegenerative diseases were revealed by studies of individual disease determinants. For example, in some patients HIV infection was shown to correlate with the presence of leukoencephalomyelopathy and MS-like illness (Berger et al. [@CR4]; Corral et al. [@CR13]). In a recent cross-sectional cohort study, HAND was shown to correlate with presence of auto-antibodies to myelin oligodendrocyte glycoprotein, including in patients on ART with suppressed plasma HIV (Lackner et al. [@CR51]), suggesting that HAND and MS neuropathogenesis may overlap in the pathway of aberrant myelin breakdown. Consistent with this finding, our recent microarray analysis of brain tissues from HAND patients on ART revealed significant down-modulation of several myelin metabolism-related genes including myelin-associated oligodendrocyte basic protein (MOBP), myelin transcription factor 1 (MYT1) and myelin basic protein (MBP) (Borjabad et al. [@CR8]). On the other hand, HIV Tat was shown to inhibit neprilysin and elevate amyloid-beta in fetal human brain spheres in culture and amyloid-beta was elevated in postmortem brain tissues of patients with HAND (Rempel and Pulliam [@CR76]), suggesting one common pathway in HAND and AD pathogenesis in older individuals. This notion is supported by recent proteomic analysis of postmortem frontal cortex tissues from HIV positive patients with or without HAD, which revealed aberrant expression of proteins involved in glycolysis and oxidative phosphorylation specifically in HAD tissues and noted similar pathway changes in other dementia conditions including Alzheimer's and Parkinson's diseases (Zhou et al. [@CR101]). Broader patterns of similarity between HAND and diseases such as AD and MS were suggested based on review of macrophage/microglia and astrocyte functions in neuropathogenesis (Minagar et al. [@CR62]), review of dysregulation of specific genes in these pathologies (Minagar et al. [@CR63]), and bioinformatics-aided analysis of potential parallels in chromosomal localization, expression and function of dementia-associated genes between HAND and AD (Shapshak et al. [@CR86]). Indeed, a recent review by Noorbakhsh et al. presented a convincing case for the power of integrative analysis of data-rich studies involving functional genomics, proteomics, and other systems biology approaches in discerning convergent pathways of human neuropathogenesis (Noorbakhsh et al. [@CR68]).

In the present study we used publicly available functional genomic data and bioinformatics tools to conduct for the first time a comparative analysis of gene expression profiles of brain tissues of HAND, AD, and MS. Genome-wide microarray analysis of coordinated changes in gene expression is one of the most established platforms for integrated understanding of global phenotypic changes occurring during transition from normal to pathological states, including in the central nervous system (D'Agata and Cavallaro [@CR16]; Grunblatt [@CR31]; Blalock et al. [@CR6]; Noorbakhsh et al. [@CR68]; Bossers et al. [@CR9]; Cooper-Knock et al. [@CR12]). Our objective was to identify altered gene expression motifs in brain tissues that may indicate convergence of pathogenic mechanisms driving development of HAND and one or both of the other two neurodegenerative conditions in this study. A rich microarray database from multiple studies exists for AD and MS (for reviews, see (Katsel et al. [@CR45]; Lindberg and Kappos [@CR52]; Tajouri et al. [@CR93]; Kinter et al. [@CR49])). The respective database from HAND brain tissues is less extensive but it nevertheless encompasses analyses of over 60 HAND patients and controls in five studies (Gelman et al. [@CR27]; Masliah et al. [@CR60]; Shapshak et al. [@CR85]; Everall et al. [@CR24]; Borjabad et al. [@CR8]). The meta-analysis of these datasets revealed numerous aberrant gene expression changes and alterations in biological pathways that were common to HAND and AD and HAND and MS in two-way analyses, and that were overlapping for all three diseases in a three-way comparison.

Materials and methods {#Sec2}
=====================

Selection of gene expression datasets from brain tissues of individuals with HAND, AD, and MS for comparative analysis {#Sec3}
----------------------------------------------------------------------------------------------------------------------

The microarray studies of the three neurodegenerative diseases of interest were identified through search of publicly available gene expression databases, primarily PubMed and Gene Expression Omnibus (GEO) at the National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/>). The studies selected for this work are listed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. We considered only microarray studies conducted with human post-mortem brain tissue, excluding animal and tissue culture models of these diseases. The choice of brain anatomical regions included in our analyses is explained in [Results](#Sec5){ref-type="sec"}. To facilitate comparison among diverse microarray datasets only studies that used control groups and expressed results as differential gene expression (fold change) between tested biological state and control were selected. Finally, we excluded studies that provided insufficient information about microarray analysis.Table 1Published gene expression profiles from HAND brain tissues used in the present analysisAuthorYearBrain area testedMicroarray platformBiological states comparedMasliah2004Frontal cortexAffymetrix U95Av2HIVE vs non HIVEGelman2004Frontal cortex and white matterAffymetrix HG-U133HAND-MCMD-NPI-O vs HIV negShapshak2004Frontal cortexAffymetrix U95Av2HIV vs HIV negEverall2005Frontal cortexAffymetrix U95Av2HIVE vs non HIVEBorjabad2011Frontal lobe white matterAffymetrix HG-U133untreated HAND vs HIV negBorjabad2011Frontal lobe white matterAffymetrix HG-U133treated HAND vs HIV neg5 papers: 1132 up-regulated and 779 down-regulated genesTable 2Published gene expression profiles from AD and MS brain tissues used in the present analysisAuthorYearBrain area testedMicroarray platformBiological states comparedAlzheimer's diseaseHata2001HippocampusIncyte Pharmaceuticals, UniGem V microarrayAD vs non ADLoring2001Amygdala/cingulate cortexIncyte Genomics, Unigene LifearrayAD vs non ADHo/Pasinetti2001CortexIncyte Pharmaceuticals, UniGem V microarrayearly/moderate AD vs non ADColangelo2002Hippocampus CA1Affymetrix U95AAD vs non ADWalker2004Frontal CortexThe Microarray Center, University Health Network, TorontoAD vs non ADRicciarelli2004Frontal CortexClontech, Atlas Human 12K MicroarrayAD vs non AD with amyloid plaquesLukiw2004HippocampusAffymetrix U95Afetal - adult - ADSmall2005Entorhinal cortex/dentate gyrusAffymetrix HG-U133AD vs non ADEmilsson2006Frontal CortexUppsala University and Royal Institute of TechnologyAD vs non ADParachikova2007Frontal Cortex/HippocampusAffymetrix U95Amild-moderate AD vs non AD high pathologyKatsel200717 regionsAffymetrix HG-U133different stages AD vs non ADBrooks2007HippocampusAffymetrix HG-U133metabolic genesWeeraratna2007Parietal lobes Agilent Human 44K microarraylate AD vs non-AD dementia or non ADGrünblatt2007Hippocampus, gyrusfrontalismedius, cerebellumAffymetrix HG-U133AD and PD vs non AD non PDKatsel200915 regionsAffymetrix HG-U133youngest-old/oldest-old AD and non ADWilliams2009Synaptoneurosomes from Prefrontal CortexAffymetrix HG-U133incipient AD vs non ADTan2010Neocortex (temporal cortex)Affymetrix GeneChip Human Exon 1.0 ST ArraysAD vs non ADBossers2010Prefrontal CortexAgilent Human 44K microarraycomparison different AD stages18 papers: 5185 up-regulated and 3684 down-regulated genes Multiple sclerosisWhitney1999White matterCustom-made cDNA microarraysacute lesions vs normal white matterLock2002White matterAffymetrix HuGeneFL7026 microarraysMS active or silent lesions vs controlTajouri2003White matterCustom-made fluorescent cDNA microarraysMS chronic or acute lesions vs controlMycko2003White matterClontech Atlas Glass Human 1.0Margin/centre - active/silent lesionsGraumann2003White matterClontech Atlas cDNA Expression Arraynormal-appearing vs controlLindberg2004White matterAffymetrix U95Anormal-appearing and active lesions vs controlDutta2006/2007CortexAffymetrix HG-U133MS vs controlZeis2008White matterClontech Atlas cDNA Expression Arraynormal-appearing vs controlTorkildsen2010CortexApplied Biosystemsnormal-appearing and lesions vs controlHuman Genome Survey Microarray v1.09 papers: 3922 up-regulated and 4171 down-regulated genes

Meta-analysis of gene expression profiles {#Sec4}
-----------------------------------------

The microarray datasets selected for the current analysis were obtained on various microarray platforms that used different experimental protocols and analytical methods (for example, (Masliah et al. [@CR60]; Stephens et al. [@CR90]; Bossers et al. [@CR9])); the microarray platforms are listed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. To overcome the difficulty inherent in comparing raw microarray datasets from a variety of sources (Tan et al. [@CR94]; Parmigiani et al. [@CR72]; Borjabad et al. [@CR7]), we elected to use second-level derivative datasets representing statistically significant changes in gene expression for each disease under study. Such changes are calculated according to widely acceptable standards for defining statistical significance of differential gene expression (Blalock et al. [@CR6]; Hoheisel [@CR37]) and thus this approach allowed us to compare various datasets independently of microarray platform or statistical approach used. To further facilitate comparison of genes listed by various sources, we standardized gene nomenclature in the present work to GenBank gene symbol identifiers (<http://www.ncbi.nlm.nih.gov/genbank/>). This permitted us to overcome the inconsistencies of gene nomenclature and to normalize gene identity across the datasets. It should be noted that some of the genes listed in the present analysis have a different gene ID than in the original report as a result of public database updates. Following these preparatory analyses, we pooled the sets of differentially expressed genes listed in each publication within each brain disease group (HAND, treated HAND, AD, and MS). Because our purpose was to generate a comprehensive, brain disease-specific transcriptome incorporating multiple independent studies, we listed each significantly aberrant gene in a given disease group only once and did not assign to genes any additional value besides direction of dysregulation, regardless of whether they were listed in one or multiple publications. The HAND, AD, and MS profiles were then compared in two-way and three-way analyses using the Microsoft database management system Access software to identify common (overlapping) genes. The final common gene datasets were then analyzed by functional categorization of gene families using gene ontology program Expression Analysis Significance Explorer (EASE) (Hosack et al. [@CR41]) (<http://david.abcc.ncifcrf.gov/>) and the Affymetrix NetAffx™ Analysis Center (<http://www.affymetrix.com/analysis/index.affx>).

Results {#Sec5}
=======

Brain transcriptome profiles in HAND and ART-HAND {#Sec6}
-------------------------------------------------

As of this writing, five published reports employed functional genomics to examine gene expression profiles in brain tissues from patients who died with HAND (Gelman et al. [@CR27]; Masliah et al. [@CR60]; Shapshak et al. [@CR85]; Everall et al. [@CR24]; Borjabad et al. [@CR8]); these reports are listed in Table [1](#Tab1){ref-type="table"}. The Table also provides information on the anatomical brain region and microarray platforms used, and the biological states compared in each study. Three studies examined gene expression patterns in the frontal cortex; one study tested both cortex and subcortical white matter, and one study focused on deep white matter from the frontal lobe region. Three studies used the Affymetrix U95Av2 microarray platform and two were conducted with the new-generation Affymetrix HG-U133 platform. Two HAND array studies used in our analysis show relatively limited sets of gene expression data focusing on the specific HAND disease pathology of HIV-associated encephalitis, HIVE (Masliah et al. [@CR60]; Everall et al. [@CR24]). The initial HIVE analysis employed datasets from HAD patients without HIVE as controls (no HIV negative controls were used), and it identified a total of 133 differentially expressed genes specific to HIVE (Masliah et al. [@CR60]). A follow-up study in the same patient cohort stratified microarray datasets by patient methamphetamine addiction, demonstrating a strong correlation between drug use and induction of interferon-related genes (Everall et al. [@CR24]). Additional studies based on HIVE-specific datasets were not included because they focus on individual genes already represented in these arrays rather than new array analyses (Everall et al. [@CR25]; Salaria et al. [@CR83]). Two other studies listed in Table [1](#Tab1){ref-type="table"} (Gelman et al. [@CR27]; Shapshak et al. [@CR85]) examined HIV-infected versus uninfected brain tissues; although these works show only partial datasets or derivative analyses they were included to increase the power of our analysis. The most recent study listed in Table [1](#Tab1){ref-type="table"} (Borjabad et al. [@CR8]) analyzed postmortem HAND brain tissue versus HIV negative controls; patient datasets were stratified by the antiretroviral treatment (ART) status of subjects at the time of death. This approach yielded two distinct HAND brain microarray profiles, one representing untreated patients and consisting of 1,470 dysregulated genes and the second representing treated patients and consisting of 253 dysregulated genes, the majority of which were also dysregulated in untreated subjects (Borjabad et al. [@CR8]). To construct the representative HAND brain profile for comparison with AD and MS profiles, we pooled all datasets listed in Table [1](#Tab1){ref-type="table"} including transcriptomes from both treated and untreated patients described in Borjabad et al. (Borjabad et al. [@CR8]). This approach was taken because the other HAND studies listed in Table [1](#Tab1){ref-type="table"} did not provide information on ART status of their patient cohorts and thus they could include either treated, untreated, or both categories of patients. This profile was termed HAND and it was found to consist of (excluding multiply listed genes, see Methods) 1,132 up-regulated and 779 down-regulated HAND-associated genes (Table [1](#Tab1){ref-type="table"}).

Because ART clearly mitigated cellular gene expression in the brain of patients with HAND compared to that in untreated patients (Borjabad et al. [@CR8]), we designated a second category of HAND transcriptomes called ART-HAND which contained only datasets of HAND patients known to be on treatment prior to death. Patients in this category, in a single study published so far, continued to manifest cognitive disease in the last evaluation prior to death (Borjabad et al. [@CR8]). These results were interpreted as being indicative of fundamental gene expression changes in the brain leading to HAND (Borjabad et al. [@CR8]) and they could possibly be involved in AD and MS as well. The ART-HAND dataset contains 128 significantly up-regulated and 125 down-regulated genes (Borjabad et al. [@CR8]).

Transcriptome profiles in AD and MS {#Sec7}
-----------------------------------

Table [2](#Tab2){ref-type="table"} lists microarray studies in AD and MS brain tissues selected for comparison with HAND transcriptomes. The criteria for study selection are described in Methods and below. The Table also provides information on the anatomical brain region and microarray platform used, and the biological states compared in each study. AD is at present the most common form of dementia including progressive memory loss, decline in cognitive functions, and other behavioral symptoms. Gene and protein changes in AD have been extensively studied and numerous functional genomics analyses have also been reported including studies in animal models of AD (Jee et al. [@CR42]; Prinzen et al. [@CR74]; Tseveleki et al. [@CR96]), isolated brain cells (Counts et al. [@CR14]; Ginsberg et al. [@CR28]), and post-mortem human brain tissue. In human AD brain, the main areas of analysis are the cortex (Pasinetti [@CR73]; Walker et al. [@CR97]; Emilsson et al. [@CR22]) and hippocampus (Colangelo et al. [@CR11]; Blalock et al. [@CR5]; Brooks et al. [@CR10]), two areas implicated in the pathobiology of AD. Other studies analyzed and compared different areas of the brain (Grunblatt et al. [@CR32]; Katsel et al. [@CR46]; Parachikova et al. [@CR70]), or focused on specific molecules and treatments (for review of AD functional genomic studies see (Katsel et al. [@CR45])). Given the large number of microarray studies in AD brain tissues, we selected 18 analyses of cortex and hippocampus representing a broad scope of AD conditions studied, including comparisons of AD stages, different AD pathologies, AD in young vs. old individuals, and others (Table [2](#Tab2){ref-type="table"}). The studies used a variety of microarray platforms including those from Incyte Pharmaceuticals, Incyte Genomics, Clontech, Agilent, and Affymetrix, and others (Table [2](#Tab2){ref-type="table"}). Only studies containing complete microarray analysis and data in format suitable for this meta-analysis were selected. The microarray datasets from the selected AD studies were pooled and multiply listed genes were excluded, yielding what we define here as the representative AD transcriptome profile. This profile contained 5,185 up-regulated and 3,684 down-regulated genes (Table [2](#Tab2){ref-type="table"}).

MS is a chronic inflammatory disease of the central nervous system mainly affecting white matter in which autoreactive T cells attack the myelin-oligodendrocyte complex (for review see (Noseworthy et al. [@CR69])). Several microarray studies employed mouse models of MS or cells (for reviews see (Steinman and Zamvil [@CR89]; Mix et al. [@CR64])); in addition a large number of studies evaluated gene expression in human brain tissue from patients with MS (for review see (Lindberg and Kappos [@CR52]; Tajouri et al. [@CR93]; Kinter et al. [@CR49]; Dutta and Trapp [@CR17])). These investigations involved both white (Graumann et al. [@CR30]; Tajouri et al. [@CR92]; Lindberg et al. [@CR53]) and grey matter (Dutta et al. [@CR18]; Dutta et al. [@CR19]; Torkildsen et al. [@CR95]). Some of these studies analyzed genes altered in acute, chronic or silent lesions or normal tissue. For the present meta-analysis we selected nine representative sets of genes from papers listed in Table [2](#Tab2){ref-type="table"}. Similar to AD studies, a wide variety of microarray platforms were used. The microarray datasets from all nine studies were pooled and multiply listed genes were excluded, yielding what we define here as the MS transcriptome profile; this profile consisted of 3,922 up-regulated and 4,171 down-regulated genes (Table [2](#Tab2){ref-type="table"}).

Two-way analysis of an overlap in gene and biological process dysregulation between HAND and AD and HAND and MS {#Sec8}
---------------------------------------------------------------------------------------------------------------

The transcriptome profiles of HAND and ART-HAND were each compared pairwise with AD and MS transcriptomes (Table [3](#Tab3){ref-type="table"}). A substantial number of dysregulated HAND genes in both HAND groups were also dysregulated in AD and MS profiles, with the actual number of common changes depending in part upon the number of genes present in the groups tested (Table [3](#Tab3){ref-type="table"}). The individual lists of genes in these groups, including Gene Symbol, Gene Title, and the gene ontology annotations: "Entrez Gene ID" from NCBI and "GO ID" from the Gene Ontology (GO) Consortium, are provided under separate tabs in Online Resource [1](#MOESM1){ref-type="media"}. A total of 665 or 35 % of altered genes identified in HAND brain and 49 or 19 % of treated HAND were also dysregulated in AD. The proportion of common up- and down-regulated genes in HAND and AD was about equal but marked differences were found upon pairing ART-HAND and AD, where the proportions were 28 % and 10 %, respectively. The respective frequencies of HAND genes dysregulated in common with MS, 254 out of 1,911 genes or 13 %, were much lower than those for HAND/AD pairing. Interestingly, however, there were more common down-regulated genes in ART-HAND and MS than in ART-HAND and AD, 22 versus 13, respectively (Table [3](#Tab3){ref-type="table"}).Table 3Number and percentage of dysregulated genes in brain tissues of HAND or ART-HAND in common with AD or MSAlzehimer's disease (8,869 genes)Multiple sclerosis (8,093 genes)AllUpDownAllUpDownHAND (1911 genes)66535 %38134 %28436 %25413 %17015 %8411 %ART-HAND (253 genes)4919 %3628 %1310 %4317 %2116 %2218 %

To confirm the observed commonalities between the HAND, AD, and MS at the single gene level, we performed pairwise (HAND subgroups to AD and HAND subgroups to MS) functional categorization of gene families by EASE (Table [4](#Tab4){ref-type="table"}). The five common most significantly up and down-regulated biological pathways are listed in Table [4](#Tab4){ref-type="table"}; a full list of common dysregulated pathways is provided in Online Resource [2](#MOESM2){ref-type="media"} under category-specific tabs. Consistent with a single-gene analysis, HAND, AD, and MS shared a large number of dysregulated cellular processes; however, in pairwise comparisons the identity, the relative ranking, and the extent of process sharing as indicated by the EASE score were different. For example, while the top four ranking dysregulated processes shared by HAND, AD, and MS were immune response, antigen presentation, and responses to bio- and external stimuli, the statistical significance of pair-wise sharing of these processes reflected in the EASE Score (ES) ranged from 1.36 × 10^−30^ to 2.82 × 10^−23^ for the HAND-AD pair and from 4.97 × 10^−07^ to 1.33 × 10^−05^ for the HAND-MS pair (Table [4](#Tab4){ref-type="table"} and Online Resource [2](#MOESM2){ref-type="media"}). The differences between paired HAND-AD and HAND-MS transcriptomes were even more pronounced for common down-regulated biological pathways. HAND and MS shared only five down-modulated pathways in the brain, all with the low level of statistical significance of just under ES of 0.05. Three of these pathways involved calmodulin, which in the central nervous system is known to regulate processes related to synaptic plasticity (Xia and Storm [@CR99]). In contrast, HAND and AD shared 89 down-regulated processes with ES scores under 0.05; while the five most significant of these also included processes related to synaptic function (i.e., synaptic transmission and synaptic vesicle), their ES scores ranged from 3.48 × 10^−12^ to 7.59 × 10^−10^. The calmodulin binding pathway was ranked \#8 in the HAND-AD pairing with significance score of 1.75 × 10^−8^ whereas this pathway was \#4 in HAND-MS with a score of 0.044 (Table [4](#Tab4){ref-type="table"} and Online Resource [2](#MOESM2){ref-type="media"}).Table 4Five most significant up-regulated (bold) and down-regulated (italic) biological pathways in common in HAND and AD or MS and ART-HAND and AD or MSAlzheimer's diseaseMultiple sclerosisGene categoryEASE scoreGene categoryEASE scoreHAND**immune response1.36E-30response to external stimulus4.97E-07defense response2.25E-28immune response2.83E-06response to biotic stimulus3.10E-28response to biotic stimulus3.63E-06response to external stimulus2.82E-23defense response1.33E-05antigen presentation5.30E-19response to stress0.0007***transmission of nerve impulse3.48E-12calmodulin-dependent protein kinase Iactivity0.010synaptic transmission1.43E-11non-kinase phorbol ester receptoractivity0.013transport1.15E-10calcium/calmodulin-dependent kinase activity0.033cell-cell signaling2.91E-10calmodulin binding0.045synaptic vesicle7.59E-10phorbol ester receptor activity0.046*ART-HAND**antigen presentation1.20E-05immune response0.002antigen processing1.20E-05defense response0.003signal transducer activity7.17E-05response to biotic stimulus0.005immune response0.0002response to external stimulus0.021defense response0.0004antigen processing0.022***DNA helicase activity0.018intracellular signaling cascade0.005hydrolase activity0.025signal transduction0.012cell growth and/or maintenance0.036catalytic activity0.015binding0.038cell communication0.038cellular process0.045*Gene ontology analysis was performed using EASE software (Hosack et al. [@CR41]). The complete list of dysregulated pathways is in Online Resource [2](#MOESM2){ref-type="media"}.

Consistent with our analysis at the single gene level (Table [3](#Tab3){ref-type="table"}), ART-HAND shared fewer dysregulated biological pathways with AD and MS and the statistical power of the pathways in common that remained (such as immune response) was also lower (Table [4](#Tab4){ref-type="table"} and Online Resource [2](#MOESM2){ref-type="media"}). The loss of similarity was the greatest for down-modulated biological pathways in paired ART-HAND versus AD analysis, where only four dysregulated pathways remained in common at low significance level (compared to 89 dysregulated pathways in HAND-AD pairing), and none of them representing the highly significant common dysregulation of neuronal functions (Table [4](#Tab4){ref-type="table"} and Online Resource [2](#MOESM2){ref-type="media"}). It should be noted that ART-HAND transcriptomes showed similarly attenuated dysregulation of gene expression when compared to transcriptomes form untreated HAND, a finding that we attributed to the beneficial effects of antiretroviral treatment (Borjabad et al. [@CR8]). There is as yet no treatment alleviating molecular and cognitive symptoms of AD. In this context, because ART-HAND transcriptomes are more similar to those of HIV-negative individuals than people with untreated HAND (Borjabad et al. [@CR8]), the results of comparative analysis of ART-HAND and AD profiles in the present work also can be seen as a specificity control for the HAND-AD comparison.

The analyses presented so far indicate that untreated HAND and AD, more than HAND and MS, share dysfunctions in many "executive" biological pathways responsible for defective neurocognitive functions. To obtain a more detailed view of neuropathobiological mechanisms potentially shared by these patients, we analyzed down-regulated data using gene ontology tool Affymetrix NetAffx™ Analysis Center (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). Only selected genes are shown; the full lists of aberrant genes used for this analysis are provided under dedicated tags in Online Resource [1](#MOESM1){ref-type="media"}. We found that 61 % of down-regulated pathways shared by HAND and AD were implicated in broadly-defined nervous system functions such as synaptic transmission, nervous system development, and neurocognition processes (Fig. [1](#Fig1){ref-type="fig"}). 29 % of shared dysregulated brain processes included genes involved mostly in basic cell-physiological functions such as signal transduction and cell cycle, while 10 % of common defective processes remain yet to be defined (Fig. [1](#Fig1){ref-type="fig"}). As shown in Fig. [2](#Fig2){ref-type="fig"}, the overall distribution of pathway-categorized similarities between HAND and MS was different from that of HAND and AD, with only 37 % (versus 61 % in HAND-AD) of common pathways related to nervous system function and a larger proportion (40 % versus 29 %) related to basic cellular processes. Smaller categories (under 10 %) included calcium transport and metabolism and cell adhesion (Fig. [2](#Fig2){ref-type="fig"}). Notably, even within similar broad categories of biological pathways, the majority of aberrant genes identified as common in HAND and MS were different from those common to HAND and AD (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Fig. 1Common down-regulated genes/pathways in HAND and AD. Down-regulated genes in common in HAND and AD were classified in biological pathways using the Affymetrix NetAffx™ Analysis Center (<http://www.affymetrix.com/analysis/index.affx>)Fig. 2Common down-regulated genes/pathways in HAND and MS. Down-regulated genes in common in HAND and MS were classified in biological pathways using the Affymetrix NetAffx™ Analysis Center (<http://www.affymetrix.com/analysis/index.affx>)

Three-way analysis of an overlap in gene and biological process dysregulation between HAND, AD, and MS {#Sec9}
------------------------------------------------------------------------------------------------------

The potential pathophysiological overlap between HAND, AD, and MS and ART-HAND, AD, and MS is shown schematically in Venn diagrams in Fig. [3](#Fig3){ref-type="fig"}. The diagrams are based on the lists of common dysregulated genes provided in Online Resource [1](#MOESM1){ref-type="media"}. There were 59 up-regulated and 21 down-regulated genes in common to HAND, AD, and MS. Gene ontology analysis of these genes (Online Resource [2](#MOESM2){ref-type="media"}) revealed common and highly significant up-regulation of immune response processes such as response to external stimulus, inflammation and innate immunity. Other up-regulated pathways included transcription regulation, cell adhesion and others. Only 5 down-regulated pathways scored significantly in all three diseases including neurogenesis in position 5. This result confirms data shown in Table [4](#Tab4){ref-type="table"} and Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} suggesting that the mechanisms of neuronal dysfunction shared between HAND and AD on the one hand and HAND and MS on the other are different. We found only 7 up-regulated and 3 down-regulated genes common to ART-HAND, AD, and MS, in part reflecting highly reduced number of dysregulated genes found in ART-treated HAND brain (Borjabad et al. [@CR8]). No significant pathways were found commonly dysregulated in these three groups.Fig. 3Common up- (*red/bold*) and down-regulated (*green/italics*) genes in HAND, AD, and MS. Venn diagrams show the common number of genes in all three diseases

Discussion {#Sec10}
==========

Comparison of gene expression profiles from brain diseases obtained by independent studies is challenging (Glanzer et al. [@CR29]; Lukasiuk and Pitkänen [@CR58]; Higgs et al. [@CR36]; Cooper-Knock et al. [@CR12]). Factors such as the heterogeneity of brain tissue, patient-to-patient variability, disease stage, anatomical location of samples, and technical and study design differences all contribute to a significant variability among individual studies (Glanzer et al. [@CR29]; Lukasiuk and Pitkänen [@CR58]; Higgs et al. [@CR36]; Cooper-Knock et al. [@CR12]; Hawrylycz et al. [@CR34]). However, variability does not necessarily imply irreproducibility unless the same samples are independently analyzed and yield different results (Sorlie et al. [@CR88]), which was not reported for the array datasets used in the present work. It is likely that individual array analyses for the same disease may represent gene profile snapshots of specific physiological situations tested at different disease stages or different brain anatomical sites, as we recently suggested for transcriptomes of white and grey matter from brain tissues of patients with advanced HAND (Borjabad et al. [@CR8]). With these caveats, we considered such non-overlapping gene expression data from the same disease as cumulative hits of gene dysregulation for inferring tentative representative molecular profiles of HAND, AD, and MS. Having identified specific transcripts modulated in common among these diseases in the present study, future studies can conduct more tailored analysis to compare similar microarray platforms, similar brain regions, patients at similar ages, or sharing other features likely to influence the analysis of the outcome of disease. Such studies have recently been published, for example, for AD and schizophrenia (Park et al. [@CR71]; Roussos et al. [@CR80]) and are under way for HAND in our laboratory.

One major outcome of our analysis is the demonstration of significant similarity between HAND and AD at the brain transcriptome level despite different etiologies of these diseases. HAND is a virally-induced disease in which soluble factors produced by HIV infected/activated macrophages, microglia, and astrocytes induce brain inflammation, disrupt brain homeostasis, mediate neuronal and astrocyte dysfunction, and in advanced disease lead to neuronal and astrocyte apoptosis and dementia (Lipton and Gendelman [@CR54]; Lopez-Villegas et al. [@CR55]; Ellis et al. [@CR21]; Sailasuta et al. [@CR82]; Borjabad et al. [@CR8]). Thus HAND pathogenesis appears to be driven primarily by environmental insults to neurons and neuronal-astrocyte networks. In contrast, AD is primarily an auto "proteopathic" (Jucker and Walker [@CR44]) neurodegenerative disease initiated in neurons by misfolding and aggregation of two specific proteins, amyloid-beta and tau, which in later stages of disease form the characteristic lesions of senile plaques and neurofibrillary tangles (Maccioni et al. [@CR59]; Jucker and Walker [@CR44]; Wilcox et al. [@CR98]). Inflammation plays a prominent role in AD but it appears to be secondary to amyloid-beta and tau accumulation (Khandelwal et al. [@CR48]; Zilka et al. [@CR102]). Yet our results suggest that the pathophysiology of HAND and AD converges in a relatively limited number of down-regulated genes responsible for dysfunctions linked to neuronal function and neurodegeneration including synaptic plasticity, synaptic signal transmission, and axonal transport (Fig. [1](#Fig1){ref-type="fig"}). Indeed, synaptodendritic injury and synaptic failure are believed to underlie neurocognitive impairment in both HAND and AD (Selkoe [@CR84]; Ellis et al. [@CR21]; Wilcox et al. [@CR98]). In AD, synaptic failure was correlated with accumulation and post-synaptic binding of beta-amyloid oligomers (Wilcox et al. [@CR98]; Yu and Lu [@CR100]) and accumulation of phosphorylated tau in dendritic spines (Hoover et al. [@CR39]). The mechanisms of synaptic injury in HAND are not fully understood but role of factors secreted by HIV-infected macrophages including HIV Tat protein and platelet-activating factor has been suggested (Lu et al. [@CR56]; Lu et al. [@CR57]). Regardless of the proximal stimuli for synaptic injury, these results support the notion that some core cellular processes mediating this impairment in HAND and AD are similar.

In contrast to HAND and AD, while both MS and HAND share pathologies of white matter (Navia et al. [@CR67]; Noseworthy et al. [@CR69]) they largely diverge in their respective molecular phenotypes of disease. The divergence is consistent with the generally distinct disease phenotypes of HAND and MS; HAND presents cognitive and behavioral impairments with varying motor involvement (Navia et al. [@CR66]) while MS is mostly known as a debilitating motor and sensory disease (for review see (Noseworthy et al. [@CR69])). It has been recently recognized that MS also involves cognitive impairment (Noseworthy et al. [@CR69]), and indeed our analysis shows overlap between HAND and MS in dysregulation of genes involved in synaptic calcium processing (Fig. [2](#Fig2){ref-type="fig"}).

Relatively few genes were dysregulated in common in the three diseases analyzed here and they may represent key pathways involved in neurodegeneration. Most prominent among common up-regulated pathways were immune responses, including increased expression of CD14, CD44, MHC class I and II genes HLADQA1 and B2M, interferon response-related genes IRF2 and IL10RB, and complement component C4B (Online Resources [1](#MOESM1){ref-type="media"} and [2](#MOESM2){ref-type="media"}). Our analysis extends previous reports on individual gene products and functions (Hoozemans et al. [@CR40]; Reynolds et al. [@CR77]) consistent with the notion that immune responses and chronic neuroinflammation are common denominators of HAND, AD and MS. Also notable was common up-regulation of BACE2, a gene coding for an amyloid-beta peptide that was previously linked to Alzheimer's disease (Holler et al. [@CR38]). Common down-regulated genes in HAND, AD, and MS revealed by our analysis are primarily linked to neuronal and especially synaptic functions consistent with the common neurocognitive impairment in the three diseases (Navia et al. [@CR66]; Noseworthy et al. [@CR69]; Maccioni et al. [@CR59]), including CBLN2, GPM6A and CUTL2, genes linked to synapse formation and differentiation and implicated in memory processes (Cubelos et al. [@CR15]); neuronal development genes LZTS1 and NAP1L3 (Attia et al. [@CR3]; Kropp and Wilson [@CR50]); and the DDP6 gene that participates in regulation of potassium-related dendritic excitability (Sun et al. [@CR91]). Other common down-regulated genes include calcium-related genes CAMK2G, CACNA2D3 or CADPS2 potentially implicated in the control synaptic plasticity and long term potentiation through sequestration of intracellular calcium (Kawamoto et al. [@CR47]). Of particular interest was suppression of the GABA receptor GABRG2, potentially impairing GABAergic neuron signal transmission and memory (Melzer et al. [@CR61]) and dysregulation of the UBE3A gene that was previously implicated in proteasome degradation and linked to the cognitive impairment of Angelman syndrome (Jiang et al. [@CR43]). Also of note, the three diseases shared down-modulation of hemoglobin B which was recently described as a new marker of neurodegeneration in Alzheimer's disease and other dementias (Ferrer et al. [@CR26]).

Clearly, additional independent analyses with larger datasets and confirmatory RNA and protein assays are needed to substantiate these results. Nevertheless, our work indicates that there might be a core of dysregulated processes in the brain that are common to the three very different neurodegenerative disorders analyzed in the present work. Convergent pathogenic pathways were recently suggested for AD and Huntington's disease (Ehrnhoefer et al. [@CR20]). Better understanding of such putative shared processes of neuropathogenesis may direct development of novel disease prevention strategies and treatments.
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Online Resource 1Common genes in HAND, AD and MS and ART-HAND, AD and MS transcriptomes. List of the GenBank (NCBI website) "Gene Symbol", "Gene Title" and "Entrez Gene ID" identifiers, and the "GO ID" from the Gene Ontology Consortium (http:[www.geneontology.org](http://www.geneontology.org)) for the common transcripts in HAND, AD and MS or ART-HAND, AD and MS. The datasets are listed in different sheets of the Excel file. (XLS 603 kb)

Online Resource 2Gene ontology analysis of genes commonly regulated in HAND, AD and MS and ART-HAND, AD and MS. List of significant common up and down-regulated pathways in HAND, AD and MS or ART-HAND, AD and MS. Gene ontology analysis was performed using EASE software (Hosack et al. [@CR41]). The analysis results are listed in different sheets of the Excel file. (XLS 134 kb)
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